|
1）Gisselbrecht C, Gaulard P, Lepage, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkins lymphomas. Groupe dEtudes des Lymphomes de IAdulte (GELA). Blood. 1998; 92: 76-82
|
|
|
|
2）Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-42
|
|
|
|
|
3）Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-91
|
|
|
|
|
|
4）Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010; 16: 1520-31
|
|
|
|
|
|
5）Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003; 278: 3466-73
|
|
|
|
|
|
6）Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010; 28: 1591-8
|
|
|
|
|
|
7）Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012; 30: 837-42
|
|
|
|
|
|
8）Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007; 25: 5458-64
|
|
|
|
|
|
9）Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci. 2011; 102: 44-50
|
|
|
|
|
10）Vestergaard C, Yoneyama H, Murai M, et al. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest. 1999; 104(8): 1097-105
|
|
|
|
|
|
11）Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the trans-cription factor Foxp3. Science. 2003; 299: 1057-61
|
|
|
|
|
|
12）Yagi H, Nomura T, Nakamura K, et al. Crucial role of FOXP3 in the development and function of human CD25＋CD4＋ regulatory T cells. Int Immunol. 2004; 16: 1643-56
|
|
|
|
|
|
13）Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003; 9: 3625-34
|
|
|
|
|
|
14）Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004; 10: 5494-500
|
|
|
|
|
|
15）Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006; 97(11): 1139-46
|
|
|
|
|
|
16）Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2004; 10(22): 7529-39
|
|
|
|
|
|
17）Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer. 2007; 120: 2052-7
|
|
|
|
|
|
18）Niwa R, Hatanaka S, Shoji-Hosaka E, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of Fc gamma RIIIa functional polymorphism. Clin Cancer Res. 2004; 10: 6248-55
|
|
|
|
|
|
19）Duvic M, Pinter-Brown L, Foss FM, et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood (ASH Annual Meeting Abstracts). 2010; 116: Abstract 962
|
|
|
|
|
|
20）Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006; 66(11): 5716-22
|
|
|
|
|